key: cord-1033459-lgyz2iz6 authors: Tanaka, Akihito; Yamamoto, Shohei; Miyo, Kengo; Mizoue, Tetsuya; Maeda, Kenji; Sugiura, Wataru; Mitsuya, Hiroaki; Sugiyama, Haruhito; Ohmagari, Norio title: Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan date: 2021-01-29 journal: J Infect DOI: 10.1016/j.jinf.2021.01.010 sha: 1ccb4dd6dba7b40f16011b4d530aaf3ab3d43950 doc_id: 1033459 cord_uid: lgyz2iz6 nan We read with interest Jones et al.'s report of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) seroprevalence among health-care workers (HCWs) and support staff at North Bristol NHS Trust. 1 The authors reported 9.3% seroprevalence and its variation by ethnicity, with higher rate observed among non-White including Asian (14.6%) than White (8.2%). A large geographical variation of seroprevalence among HCW has been reported: higher in North America and Europe than Asia2. In Japan, which has relatively high number of Covid-19 cases in Asia, data are limited on the seroprevalence among HCW.3,4 National Center for Global Health and Medicine (NCGM), due to its special role in the control of infectious diseases in Japan, has been taking a leading role in combatting Covid-19 since early phase of its epidemic, and many NCGM staff have being involved in various missions with potential exposure to SARS-CoV-2, including health check of returnees on charter flights from Hubei, China5 and infection control on cruise ship Diamond Princess. 6 We designed a study comprising repeated cross-sectional surveys among staff of NCGM. Here, we report here the results of the first survey on July, 2020 (after the first wave of epidemic in Japan), which was mainly targeted for those who had worked in Covid-19 related department or was engaged in any Covid-19 related task or, or nurses of inpatient ward. Of 1,579 employees we invited, 1,228 (77.8%) agreed to participate in the survey. Written informed consent was obtained from each participant. This study was approved by the ethics committee of NCGM. We asked participants to complete an electronic questionnaire and donate venous blood. Serum separated was measured for SARS-CoV-2 antibodies by using test systems manufactured by Abbott and Roche at in-house laboratory. We run the Abbott Architect® instrument using the SARS-CoV-2 IgG assay, based on the chemiluminescent microparticle immunoassay to detect IgG against the SARS-CoV-2 nucleoprotein, and Roche cobas® e602 analyzer using the Elecsys® Anti-SARS-CoV-2 based on the electrochemiluminescence immunoassay to detect total antibodies including IgG to the SARS-CoV-2 nucleoprotein. For the sample with positive on either test, we quantified IgG with Anti-SARS-CoV-2 [anti-S1] ELISA (EUROIMMUN AG, Luebeck, Germany) and neutralizing antibody titer by using live virus. We defined antibody positive if either test shows positive (sensitivity priority). We calculated the proportion of those with antibody positive rate and its 95% confidence interval (Clopper-Pearson), and compared the seroprevalence with that of the general population survey in Tokyo, 4 which used the same assays as the current study. We also defined antibody positive if both tests are positive (specificity priority). The mean (SD) age of study participants was 36 (11) years and 71% were female. As shown in Table, major occupational categories were nurses (50%), doctor (20%), other allied health professional (13%), and administrative staff (15%). A total of 850 participants (69%) reported having being engaged in any work associated with Covid-19; of these, 343 (40%) were engaged in work with high infection risk. Of study participants, only two were positive on either antibody test; one on Abbott test (index: 2.24) and another on Roche test (index: 7.64), giving a seroprevalence of 0.16% (95% confidence interval: 0.02 to 0.59). The observed SARS-CoV-2 seropositivity is no greater than that of general population survey on June 2020 in Tokyo (0.41%, recalculated according to the current definition)3. The participants with positive test result were both female nurses aged 20's, and reported having no symptoms indicative of Covid-19, no engagement in Covid-19 related work, and no close contact with infected patient without personal protecting device. Another nurse who was previously diagnosed as Covid-19 showed negative on the present antibody test. The two positive samples on either test were proved to be negative on neither EUROIMMUNO IgG quantitative test nor neutralizing antibody test. If we adopt specificity priority-definition of antibody positive (positive on both tests), the seroprevalence is zero. A systematic review of seroprevalence studies suggested high risk of SARS-CoV-2 infection among HCW.2 In contrast, we observed a very low seropositive rate in the staff of NCGM as of July 2020, which was even lower than that among the general population in Tokyo. In a tertile hospital in the US, rate of SARS-CoV-2 infection among HCW was lower than that among the general public in the surrounding region. 8 The observed low seroprevalence may reflect effective infection control in the hospital. While having accepted a large number of inpatients and being involved in various Covid-19 related work since early phase of this epidemic, NCGM have introduced comprehensive measures to protect staff against the infection. These include sufficient provision with personal protective equipment for HCW depending on their infection risk, intensive and frequent hand washing/alcohol sanitation practice, universal masking, limiting visitors, checking body temperature at hospital entrance, notification of fever from staff on daily basis, SARS-CoV-2 PCR test for staff who reported fever or close contact with infected patient and for pre-operative patients, partitioning dining table with acrylic board, and periodic advisory e-mail message to the staff, all of which might have collectively contributed to minimizing infection risk in hospital. These measures have been upgraded according to the epidemic of the time. The staff faces high infection risk in their daily life outside hospital, which is located in the central Tokyo, an epicenter. NCGM has taken measures to address this issue. For instance, the infection control department delivers an e-mail on every Friday to all the staff to raise the awareness of preventive behaviors that should be taken during the weekend. Such advisory message might have contributed to high compliance of staff with preventive practice and lowering risk of community-acquired infection. In conclusion, this seroepidemiological study in a large hospital in Tokyo adds evidence to support that comprehensive infection control measures in hospital can decrease risk of SARS-CoV-2 infection among HCW combatting Covid-19 to the levels comparable to or even lower than that of the general population. Repeated testing of antibody among HCW is warranted to monitoring the spread of infection and to assess control measures in hospital. SARS-CoV-2 IgG seroprevalence in healthcare workers and other staff at North Bristol NHS Trust: A sociodemographic analysis Seroprevalence of SARS-CoV-2 antibodies and associated factors in health care workers: a systematic review and meta-analysis Survey of the current status of subclinical coronavirus disease 2019 (COVID-19) SARS-CoV-2 IgG seroprevalence among medical staff in a general hospital that treated patients with COVID-19 in Japan: retrospective evaluation of nosocomial infection control SARS-CoV-2 infection among returnees on charter flights to Japan from Hubei Epidemiology and quarantine measures during COVID-19 outbreak on the cruise ship Diamond Princess docked at Yokohama, Japan in 2020: a descriptive analysis Results of a survey on SARS-CoV-2 antibody in the general population in Japan Prevalence of SARS-CoV-2 infection among health care workers in a tertiary community hospital Antibody test reagents were provided from Abbott and Roche Diagnostic to the present study. The funder did not play any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.